[CBLI] Cleveland BioLabs, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Commercial Physical & Biological Resarch

Market Capitalization: 27.15 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.6 Change: 0.04 (2.56%)
Ext. hours: Change: 0 (0%)

chart CBLI

Refresh chart

Strongest Trends Summary For CBLI

CBLI is in the long-term down -61% below S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Cleveland BioLabs, Inc., a biopharmaceutical company, focuses on developing pharmaceuticals designed to address diseases with significant medical need. Its lead drug candidates include Entolimod, which is being developed as radiation countermeasure for prevention of death from acute radiation syndrome and as an oncology drug; and CBL0137, which is in two multi-center, single agent, dose escalation Phase I studies in subjects with advanced solid tumors. The company?s clinical stage product candidates comprise CBL0102, which has completed Phase I safety and tolerability study in patients with liver metastases of solid tumors of epithelial origin, or primary advanced hepatic carcinoma; and Entolimod, which is in Phase I clinical trials for open-label, dose-escalation study designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity in advanced cancer patients. Its preclinical stage product candidates include CBLB612, a pharmacologically optimized synthetic molecule that structurall

Fundamental Ratios
Shares Outstanding10.99 M EPS-0.33 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 8.01% Sales Growth - Q/Q-56.33% P/E-9.91
P/E To EPS Growth P/S9.13 P/BV-4.97 Price/Cash Per Share
Price/Free Cash Flow-1.88 ROA-4.07% ROE7.97% ROI
Current Ratio0.52 Quick Ratio Long Term Debt/Equity-0.25 Debt Ratio-1.97
Gross Margin Operating Margin-478.01% Net Profit Margin-14.63% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities3.31 M Cash From Investing Activities40 K Cash From Operating Activities-2.23 M Gross Profit
Net Profit-3.65 M Operating Profit-3.31 M Total Assets10.68 M Total Current Assets5.58 M
Total Current Liabilities10.76 M Total Debt4.06 M Total Liabilities16.14 M Total Revenue610 K
Technical Data
High 52 week2.92 Low 52 week1.01 Last close1.41 Last change0%
RSI43.9 Average true range0.06 Beta0.86 Volume56.99 K
Simple moving average 20 days-3.69% Simple moving average 50 days-6.21% Simple moving average 200 days-9.95%
Performance Data
Performance Week-2.08% Performance Month-6.62% Performance Quart-15.57% Performance Half-7.89%
Performance Year-49.98% Performance Year-to-date39.6% Volatility daily2.82% Volatility weekly6.31%
Volatility monthly12.94% Volatility yearly44.82% Relative Volume204.46% Average Volume4.99 K
New High New Low

News

2019-11-14 16:30:00 | Cleveland BioLabs Reports Third Quarter 2019 Financial Results and Development Progress

2019-10-04 10:25:31 | Here's Why We're Watching Cleveland BioLabs's NASDAQ:CBLI Cash Burn Situation

2019-08-20 13:40:58 | Some Cleveland BioLabs NASDAQ:CBLI Shareholders Have Taken A Painful 83% Share Price Drop

2019-08-14 08:30:00 | Cleveland BioLabs Reports Second Quarter 2019 Financial Results and Development Progress

2019-06-12 10:30:11 | Is Cleveland BioLabs, Inc. NASDAQ:CBLI Overpaying Its CEO?

2019-05-25 08:15:00 | M&T Bank crossed $4 billion revenue mark to remain top Buffalo-based public company

2019-05-15 08:30:00 | Cleveland Biolabs Reports First Quarter 2019 Financial Results and Development Progress

2019-03-07 08:15:00 | Cleveland Biolabs Reports 2018 Financial Results and Development Progress

2019-02-07 11:58:22 | Does Cleveland BioLabs, Inc. NASDAQ:CBLI Have A Particularly Volatile Share Price?

2018-12-14 14:22:54 | Genome Protection received $10.5M investment from fund controlled by Roman Abramovich

2018-12-06 09:31:48 | What does Cleveland BioLabs Inc’s NASDAQ:CBLI Balance Sheet Tell Us About Its Future?

2018-11-23 07:20:00 | Market Trends Toward New Normal in support, Innovative Solutions and Support, Cleveland BioLabs, Ideal Power, Comstock Holding Companies, and GWG — Emerging Consolidated Expectations, Analyst Ratings

2018-11-14 07:30:00 | Cleveland Biolabs Reports Third Quarter 2018 Financial Results and Development Progress

2018-10-05 13:24:20 | The Cleveland BioLabs Inc NASDAQ:CBLI Ownership Structure Could Be Important

2018-08-14 17:15:00 | Cleveland Biolabs Reports Second Quarter 2018 Financial Results And Development Progress

2018-08-14 16:45:00 | Cleveland Biolabs Announces Formation and Financing of an Anti-Aging Joint Venture

2018-08-06 17:00:00 | Cleveland BioLabs Announces Delay in Analysis of Biocomparability Data Required for Regulatory Submission

2018-06-22 15:12:42 | Ikea’s departure from Cary leads to impairment charge for mall owner

2018-06-12 07:30:00 | Wired News – Alnylam Pharma Presented New Encouraging Results from Phase-1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type-1

2018-05-31 16:18:19 | Should You Be Concerned About Cleveland BioLabs Inc’s NASDAQ:CBLI Investors?

2018-05-15 08:00:00 | Cleveland Biolabs Reports First Quarter 2018 Financial Results and Development Progress

2018-04-17 14:37:18 | Is Cleveland BioLabs Inc’s NASDAQ:CBLI CEO Being Overpaid?

2018-03-28 17:05:00 | Cleveland Biolabs Announces Progress on European Marketing Authorization Application

2018-03-06 08:00:00 | Cleveland Biolabs Reports 2017 Financial Results and Development Progress

2018-02-21 16:28:24 | Should You Be Concerned About Cleveland BioLabs Inc’s NASDAQ:CBLI Investors?

2018-02-09 14:02:15 | Have Investors Already Priced In Healthcare Growth For Cleveland BioLabs Inc NASDAQ:CBLI?

2018-01-01 14:45:08 | Is Cleveland BioLabs Inc’s NASDAQ:CBLI CEO Incentives Align With Yours?

2017-12-29 11:40:01 | ETFs with exposure to Cleveland BioLabs, Inc. : December 29, 2017

2017-12-22 16:55:12 | Is Cleveland BioLabs Inc NASDAQ:CBLI As Financially Strong As Its Balance Sheet Indicates?

2017-12-13 12:55:24 | ETFs with exposure to Cleveland BioLabs, Inc. : December 13, 2017

2017-12-01 07:00:00 | Wired News – FDA Cleared IND Application of Capricor to Conduct Phase-2 Trial of CAP-1002 for Duchenne Muscular Dystrophy

2017-11-30 13:36:58 | ETFs with exposure to Cleveland BioLabs, Inc. : November 30, 2017

2017-11-29 08:17:47 | Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017

2017-11-22 20:40:34 | What Does Cleveland BioLabs Inc’s CBLI Ownership Structure Look Like?

2017-11-15 11:38:44 | ETFs with exposure to Cleveland BioLabs, Inc. : November 15, 2017

2017-11-14 08:15:00 | Cleveland BioLabs Reports Third Quarter 2017 Financial Results and Development Progress

2017-11-08 16:49:16 | How Does Cleveland BioLabs Inc CBLI Compare To The Healthcare Sector?

2017-10-26 10:23:40 | ETFs with exposure to Cleveland BioLabs, Inc. : October 26, 2017

2017-10-11 11:17:18 | ETFs with exposure to Cleveland BioLabs, Inc. : October 11, 2017

2017-09-19 17:11:58 | ETFs with exposure to Cleveland BioLabs, Inc. : September 19, 2017

2017-09-18 12:02:25 | Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017

2017-09-11 15:57:10 | What You Must Know About Cleveland BioLabs Inc’s CBLI Risks

2017-08-11 08:00:00 | Cleveland Biolabs Countermeasure for Acute Radiation Syndrome, Pipeline Review, and Market Potential

2017-08-04 19:26:23 | ETFs with exposure to Cleveland BioLabs, Inc. : August 4, 2017

2017-07-12 14:18:45 | ETFs with exposure to Cleveland BioLabs, Inc. : July 12, 2017

2017-06-26 15:32:39 | ETFs with exposure to Cleveland BioLabs, Inc. : June 26, 2017

2017-06-16 15:31:12 | ETFs with exposure to Cleveland BioLabs, Inc. : June 16, 2017

2017-06-05 14:06:59 | ETFs with exposure to Cleveland BioLabs, Inc. : June 5, 2017

2017-06-02 10:27:51 | Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017

2017-05-15 07:30:00 | Cleveland BioLabs Reports First Quarter 2017 Financial Results and Development Progress